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A B S T R A C T
Background
Preterm infants may accumulate nutrient deficits leading to extrauterine growth restriction. Feeding preterm infants with nutrient-
enriched rather than standard formula might increase nutrient accretion and growth rates and might improve neurodevelopmental
outcomes.
Objectives
To compare the effects of feeding with nutrient-enriched formula versus standard formula on growth and development of preterm
infants.
Search methods
We used the Cochrane Neonatal standard search strategy. This included electronic searches of the Cochrane Central Register of
ControlledTrials (CENTRAL; 2018, Issue 11),MEDLINE, Embase, and theCumulative Index toNursing andAlliedHealth Literature
(until November 2018), as well as conference proceedings, previous reviews, and clinical trials databases.
Selection criteria
Randomised and quasi-randomised controlled trials that compared feeding preterm infants with nutrient-enriched formula (protein
and energy plus minerals, vitamins, or other nutrients) versus standard formula.
Data collection and analysis
We extracted data using the Cochrane Neonatal standard methods. Two review authors separately evaluated trial quality and extracted
and synthesised data using risk ratios (RRs), risk differences, and mean differences (MDs). We assessed certainty of evidence at the
outcome level using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods.
Main results
We identified seven trials in which a total of 590 preterm infants participated. Most participants were clinically stable preterm infants of
birth weight less than 1850 g. Few participants were extremely preterm, extremely low birth weight, or growth restricted at birth. Trials
were conducted more than 30 years ago, were formula industry funded, and were small with methodological weaknesses (including lack
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of masking) that might bias effect estimates. Meta-analyses of in-hospital growth parameters were limited by statistical heterogeneity.
There is no evidence of an effect on time to regain birth weight (MD -1.48 days, 95% confidence interval (CI) -4.73 to 1.77) and
low-certainty evidence suggests that feeding with nutrient-enriched formula increases in-hospital rates of weight gain (MD 2.43 g/kg/
d, 95% CI 1.60 to 3.26) and head circumference growth (MD 1.04 mm/week, 95% CI 0.18 to 1.89). Meta-analysis did not show
an effect on the average rate of length gain (MD 0.22 mm/week, 95% CI -0.70 to 1.13). Fewer data are available for growth and
developmental outcomes assessed beyond infancy, and these do not show consistent effects of nutrient-enriched formula feeding. Data
from two trials did not show an effect on Bayley Mental Development Index scores at 18 months post term (MD 2.87, 95% CI -1.38
to 7.12; moderate-certainty evidence). Infants who received nutrient-enriched formula had higher Bayley Psychomotor Development
Index scores at 18 months post term (MD 6.56. 95% CI 2.87 to 10.26; low-certainty evidence), but no evidence suggested an effect
on cerebral palsy (typical RR 0.79, 95% CI 0.30 to 2.07; 2 studies, 377 infants). Available data did not indicate any other benefits or
harms and provided low-certainty evidence about the effect of nutrient-enriched formula feeding on the risk of necrotising enterocolitis
in preterm infants (typical RR 0.72, 95% CI 0.41 to 1.25; 3 studies, 489 infants).
Authors’ conclusions
Available trial data show that feeding preterm infants nutrient-enriched (compared with standard) formulas has only modest effects on
growth rates during their initial hospital admission. No evidence suggests effects on long-term growth or development. The GRADE
assessment indicates that the certainty of this evidence is low, and that these findings should be interpreted and applied with caution.
Further randomised trials would be needed to resolve this uncertainty.
P L A I N L A N G U A G E S U M M A R Y
Nutrient-enriched formula for preterm infants
Review question
Does feeding preterm infants with nutrient-enriched formula (extra energy and protein) compared with standard formula increase the
rate of growth and improve development?
Background
Standard formula (designed for term infants) may not provide preterm infants with sufficient quantities of nutrients to support
optimal growth and development. Nutrient-enriched formula (containing extra protein and energy from carbohydrates or fat and other
nutrients) has about 20% higher nutrient content than standard formula. Feeding preterm infants, particularly very preterm infants,
with nutrient-enriched formula might increase nutrient intake and growth rates, and might improve development.
Study characteristics
We found seven trials; most were small (involving 590 infants in total), and some were prone to bias.
Key results
Nutrient-enriched versus standard formula for preterm infants does not reduce the time taken to regain birth weight but is associated
with higher rates of weight gain and head growth (although not length gain) during neonatal unit stay after birth. Only limited data
are available for growth and developmental outcomes assessed beyond infancy, and these do not show consistent effects. No evidence
suggests other potential benefits or harms of nutrient-enriched formulas, including effects on feeding or bowel problems.
Conclusions
Although available trial data show that nutrient-enriched formulas increase growth rates of preterm infants during their initial hospital
admission, they do not provide evidence of effects on longer-term growth or development. Further randomised trials would be needed
to resolve this uncertainty.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: preterm infants
Setting: healthcare sett ing
Intervention: nutrient-enriched formula
Comparison: standard formula
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Risk with standard formula Risk with nutrient-enriched
formula
Weight gain (g/ kg/ d) Comparator MD gain was 2.43 higher (1.
60 to 3.26 higher)
- 440
(6 RCTs)
⊕⊕©©
Lowa,b
Length gain (mm/ week) Comparator MD gain was 0.22 mm/ week
higher (0.7 lower to 1.13
higher)
- 386
(5 RCTs)
⊕⊕©©
Lowa,b
Head circumference gain
(mm/ week)
Comparator MD gain was 1.04 mm/ week
higher (0.18 to 1.89 higher)
- 399
(5 RCTs)
⊕⊕©©
Lowa,b
Mental Development Index
(MDI) at 18 months
Comparator Mean MDI was 2.81 higher
(1.44 lower to 7.06 higher)
- 310
(2 RCTs)
⊕⊕⊕©
Moderatea
Psychomotor Development
Index (PDI) at 18 months
Comparator Mean PDI was 6.56 more (2.
87 to 10.26 more)
- 310
(2 RCT)
⊕⊕©©
Lowa,b
Necrot ising enterocolit is Study populat ion RR 0.72
(0.41 to 1.25)
489
(3 RCTs)
⊕⊕©©
Lowa,c
112 per 1000 31 per 1000
(66 fewer to 28 more)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect but may be substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of the ef fect
aUncertainty about methods used to generate random sequence, conceal allocat ion, and mask assessments in trials.
bModerate to high heterogeneity.
cPost hoc exclusions in two trials.
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B A C K G R O U N D
Description of the condition
Preterm infants (born before 37 weeks’ gestation), especially very
preterm infants (born before 32 weeks’ gestation), have fewer nu-
trient reserves at birth than term infants and are subject to physi-
ological and metabolic stresses that increase their nutrient needs.
Recommended nutrient requirements for preterm infants based
on intrauterine growth studies assume that the optimal rate of
postnatal growth should be similar to that of uncompromised
foetuses of an equivalent gestational age (Tsang 1993). However,
these recommended levels of nutrient input and growth are rarely
achieved. Most very preterm infants accumulate substantial en-
ergy, protein, mineral, and other nutrient deficits during their ini-
tial hospital stay (Embleton 2001; Horbar 2015). By the time
they are ready to go home, typically at around 36 to 40 weeks’
postmenstrual age, many infants are growth restricted relative to
their term-born peers (Clark 2003;Dusick 2003). Growth deficits,
which can persist through childhood and adolescence, are asso-
ciated with neurodevelopmental impairment and with poor cog-
nitive and educational outcomes (Bracewell 2008; Cooke 2003;
Farooqi 2006; Ford 2000; Hack 1991; Leppänen 2014; Trebar
2007). Preterm infants who have accumulated mineral deficits
have higher levels of metabolic bone disease and slower skeletal
growth compared with infants born at term. Some uncertainty
remains about long-term effects of such deficits on bone mass
and health (Fewtrell 2011). Furthermore, there is concern that
nutritional deficiency and growth restriction during early infancy
may have consequences for long-term metabolic and cardiovascu-
lar health (Embleton 2013; Lapillonne 2013).
Description of the intervention
Human breast milk is the recommended form of enteral nutrition
for preterm infants (AAP 2012). When sufficient human breast
milk is not available, an artificial formula, given as the sole form
of enteral nutrition or as a supplement to human breast milk,
may be used as an alternative (Klingenberg 2012). A variety of
formulas, typically adapted from cow’s milk, are available. These
vary in energy, protein, andmineral content and can be categorised
broadly as follows.
• Standard (‘term’) formulas based on the composition of
mature breast milk; the typical energy content is 67 to 70 kCal/
100 mL, the concentration of protein is about 1.4 g to 1.7 g/100
mL, and the calcium and phosphate content is about 50 mg/100
mL and 30 mg/100 mL, respectively.
• Nutrient-enriched (‘preterm’) formulas, designed to provide
nutrient intakes to match intrauterine accretion rates; these are
energy enriched (typically to about 75 to 80 kCal/100 mL),
protein enriched (2.0 to 2.4 g/100 mL) and variably enriched
with minerals, vitamins, electrolytes, and trace elements (Hay
2017).
How the intervention might work
Feeding preterm infants formula enriched with energy, protein,
minerals, and other nutrients may be expected to promote nu-
trient accretion and growth (increase in weight, length, and head
circumference). High levels of nutrient intake during this critical
period may be especially important for infants who are growth
restricted or ‘small for gestation’ at birth, are unable to consume
large quantities of milk, show slow postnatal growth, or have ad-
ditional nutritional and metabolic requirements (Agostoni 2010;
Klein 2002).
However, formula with high nutrient density might interfere with
gastric emptying and intestinal peristalsis, ormight perturb themi-
crobiome, resulting in enteral feed intolerance or increased risk of
necrotising enterocolitis (Embleton 2017;Hancock 1984;Ramani
2013; Shulhan 2017; Siegel 1984). Nutrient-enriched formula
that is poorly tolerated may reduce intake and any putative bene-
fit for growth and development. Furthermore, concern exists that
rapid ‘catch-up growth’ with accelerated weight gain might be as-
sociated with altered fat distribution and related ‘programmed’
metabolic consequences that increase long-term risks of insulin
resistance and cardiovascular disease (Doyle 2004; Euser 2005;
Euser 2008).
Why it is important to do this review
Given that early enteral nutrition strategies may affect growth and
development in preterm infants, and that uncertainty exists about
the balance between possible benefits and harms, this Cochrane
Review aimed to detect, appraise, and synthesise evidence from
randomised controlled trials (RCTs) to inform policy, practice,
and research.
This review focuses on the effects of feeding preterm infants with
nutrient-enriched formula versus standard formula during initial
hospitalisation after birth. RelatedCochraneReviews have assessed
the effects of feeding preterm infants nutrient-enriched formula
versus standard formula after hospital discharge (Young 2016),
and of providing multi-nutrient fortification of human milk for
feeding preterm infants (Brown 2016).
O B J E C T I V E S
To compare the effects of feeding with nutrient-enriched formula
versus standard formula on growth and development of preterm
infants.
5Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs or quasi-RCTs. Quasi-RCTs are trials that do not use a true
methodof randomisation and that allocate participants to the arms
of the trial based on date of birth, hospital number, or another
non-random method.
Types of participants
Preterm infants (less than 37 weeks’ gestation at birth) fed formula
(exclusively or as a supplement to human breast milk) during birth
hospitalisation.
Types of interventions
• Nutrient-enriched formula: both energy content > 72 kcal/
100 mL and protein content > 1.7 g/100 mL
versus
• Standard formula: both energy content ≤ 72 kcal/100 mL
and protein content ≤ 1.7 g/100 mL
The formula could be fed as the sole diet or as a supplement to
human breast milk. Infants in trial groups should have received
similar care but not similar types of formula. The intervention
should have been intended to continue for at least two weeks to
allow measurable effects on growth.
Types of outcome measures
Primary outcomes
Growth
• Time to regain birth weight and subsequent rates of weight
gain, linear growth, head growth, or skinfold thickness growth
up to six months post term
• Long-term growth: weight, height, or head circumference
(or proportion of infants who remain below the 10th percentile
for index population distribution, or both) assessed at intervals
from six months post term
Neurodevelopment
• Death or severe neurodevelopmental disability defined as
any one or a combination of the following: non-ambulant
cerebral palsy, developmental quotient more than two standard
deviations below the population mean, and blindness (visual
acuity < 6/60) or deafness (any hearing impairment requiring or
unimproved by amplification)
• Neurodevelopmental scores in children aged at least 12
months, measured via validated assessment tools such as Bayley
Scales of Infant and Toddler Development, Third Edition
(Bayley III), main domains (cognitive, motor, language)
• Cognitive and educational outcomes in children five years
of age or older.
Necrotising enterocolitis
Necrotising enterocolitis confirmed at surgery or at autopsy or di-
agnosed by at least two of the following clinical features (Kliegman
1987).
• Abdominal radiograph showing pneumatosis intestinalis or
gas in the portal venous system or free air in the abdomen.
• Abdominal distension with abdominal radiograph showing
gaseous distension or frothy appearance of bowel lumen (or
both).
• Blood in stool.
• Lethargy, hypotonia, or apnoea (or a combination of these).
Secondary outcomes
• Duration of birth hospitalisation (days)
• Feed intolerance during the trial intervention period that
results in cessation of enteral feeding for longer than four hours
• All-cause mortality before hospital discharge
• Measures of body composition (lean/fat mass) and growth
parameters including z-score for weight, length, and head
circumference, skinfold thickness, body mass index, and
proportion of infants who remain below the 10th percentile for
the index population distribution of weight, length, or head
circumference at 44 weeks’ postmenstrual age and beyond
• Measures of bone mineralization, such as serum alkaline
phosphatase level, or bone mineral content assessed by dual
energy X-ray absorptiometry (DEXA) at 44 weeks’
postmenstrual age and beyond
• Measures of long-term metabolic or cardiovascular health,
including insulin resistance, obesity, diabetes, and hypertension
Search methods for identification of studies
We used the standard search strategy of Cochrane Neonatal.
6Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Electronic searches
The search strategy was developed in Ovid MEDLINE and con-
sisted of terms for preterm or low birthweight infants combined
with terms for formulamilk. The searchwas limited toRCTs using
the sensitivity maximising version of the Cochrane Highly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE (Lefebvre 2011). We applied no language or date limits.
The MEDLINE search strategy was translated for use in the other
databases searched (Appendix 1).
We searched the following databases.
• MEDLINE (Ovid SP, 1946 to 9 November 2018).
• Cochrane Central Register of Controlled Trials
(CENTRAL, in the Cochrane Library; 2018, Issue 11).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL Plus) (EBSCO, 1982 to 12 November 2018).
• Embase (Ovid SP, 1974 to 9 November 2018).
• Maternity and Infant Care (Ovid SP, 1971 to 30 September
2018).
• PubMed (1966 to 12 November 2018).
In
addition, we searchedClinicalTrials.gov (http://clinicaltrials.gov/)
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP; www.who.int/ictrp/en/) on
16 November 2018 to identify ongoing and completed trials.
Searching other resources
We examined the references provided in studies identified as po-
tentially relevant. We searched the reference lists of any articles
selected for inclusion in this review to identify additional relevant
articles. We searched the abstracts from annual meetings of the
Pediatric Academic Societies (1993 to 2019), the European Soci-
ety for Paediatric Research (1995 to 2019), the UK Royal College
of Paediatrics and Child Health (2000 to 2019), and the Perinatal
Society of Australia and New Zealand (2000 to 2019). We con-
sidered trials reported only as abstracts to be eligible if sufficient
information was available from the trial report, or from contact
with study authors, to fulfil the inclusion criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
Selection of studies
We screened the title and abstract of all studies identified by the
above search strategy, and two review authors (VW and JB) inde-
pendently assessed the full articles for all potentially relevant tri-
als. We discussed any disagreements until consensus was achieved.
We excluded studies that did not meet the inclusion criteria and
listed all studies excluded after full-text assessment and reasons
for their exclusion in the Characteristics of excluded studies ta-
ble. The study selection process is illustrated in a PRISMA dia-
gram (Figure 1), and study selection was managed using Rayyan
(Ouzzani 2016).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (VW and JB, or VW and WM) used Covi-
dence to independently extract from each included study informa-
tion on design, methods, participants, interventions, outcomes,
and treatment effects(Veritas Health Innovation). We discussed
any disagreements until we reached a consensus.
Assessment of risk of bias in included studies
Two review authors (VW and JB) used Covidence to indepen-
dently assess risk of bias (low, high, or unclear) of all included trials
using the Cochrane ‘Risk of bias’ tool for the following domains
(Higgins 2017).
• Sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Any other bias.
We resolved disagreements by discussion or by consultation with
a third review author (WM or NDE). We did not exclude trials
on the basis of risk of bias. See Appendix 2 for a description of
each domain.
Measures of treatment effect
We analysed treatment effects in individual trials and reported
risk ratio (RR) and risk difference (RD) values for dichotomous
data and mean difference (MD) values for continuous data, along
with respective 95% confidence intervals (CIs). We planned to
determine the number needed to treat for an additional beneficial
outcome or the number needed to treat for an additional harmful
outcome for analyses with a statistically significant difference in
the RD.
Unit of analysis issues
The unit of analysis was the participating infant.
Dealing with missing data
Due to the age of the included studies (all published before 2000),
we did not contact any original study investigators. We imputed
missing standard deviations (SDs) using reported sample sizes and
standard error values.
Assessment of heterogeneity
Two review authors (NDE andWM) assessed clinical heterogene-
ity, and we conducted meta-analyses when both review authors
agreed that study participants, interventions, and outcomes were
similar.
We examined treatment effects of individual trials and heterogene-
ity between trial results by inspecting the forest plots. We calcu-
lated the I² statistic for each analysis to quantify inconsistency
across studies and to describe the percentage of variability in effect
estimates that may be due to heterogeneity rather than to sampling
error. When we detected high levels of heterogeneity (I² > 75%),
we explored possible sources (e.g. differences in study design, par-
ticipants, or interventions; completeness of outcome assessments).
Assessment of reporting biases
We planned to inspect funnel plots for asymmetry if data from
ten or more trials were included in a meta-analysis.
Data synthesis
We used a fixed-effect model for meta-analyses.
Summary of findings and certainty of evidence
We assessed the certainty of the body of evidence for the main
comparisons at the outcome level using the GRADE approach
(Schünemann 2013; see Appendix 3). Two review authors (JB
andWM) independently assessed the certainty of the evidence for
outcomes identified as critical or important for clinical decision-
making: growth, development, and necrotising enterocolitis.
We considered trial evidence as high certainty but downgraded
this by one level for serious (or by two levels for very serious) limi-
tations based upon design (risk of bias), consistency across studies,
directness, precision of estimates, and presence of publication bias.
We used the GRADEpro Guideline Development Tool (GDT) to
create a ‘Summary of findings’ table to report the certainty of the
evidence (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
When data were available, we planned subgroup analyses of:
• trials in which infants received formula only versus those
where formula could be given as a supplement to breast milk;
• extremely preterm (< 28 weeks’ gestation) infants versus
infants born at 29 to 36 weeks’ gestation; and
• infants with birth weight below the 10th percentile for the
reference population (‘small for gestation’) versus infants with
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birth weight at or above the 10th percentile (‘appropriate for
gestation’).
Sensitivity analysis
We planned sensitivity analyses to determine whether our findings
are affected by including only studies reporting adequate methods
(low risk of bias), defined as adequate randomisation and allocation
concealment, blinding of intervention and measurement, and less
than 10% loss to follow-up.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
We included seven trials (Kashyap 1986; Kulkarni 1984; Lucas
1989a; Lucas 1989b; Siripoonya 1989; Thom 1984; Yesilipek
1992).
One trial report is awaiting assessment (Costa 1996).
We did not identify any ongoing trials.
We excluded six full-text reports (Atkinson 1981; Duman 2000;
Haque 1987; Hering 1987; Pridham 1999; Yin 2004).
Included studies
Included trials were undertaken during the 1970s and 1980s by
investigators in neonatal units in the UK, the USA, Turkey, Thai-
land, and South Africa (see Characteristics of included studies).
Five of these trials were conducted at single centres (Kashyap 1986;
Kulkarni 1984; Siripoonya 1989; Thom 1984; Yesilipek 1992).
Two trials were conducted across two centres (Lucas 1989a; Lucas
1989b).
Participants
In total, 590 infants participated in the included trials (range, 22
to 264). Of these, 444 infants (> 75%) participated in the two
largest trials (Lucas 1989a; Lucas 1989b). Most participants were
clinically stable preterm infants of birth weight less than 1850
g. Few participants were extremely preterm, extremely low birth
weight, or growth restricted. The trials, in general, excluded from
participation infants with congenital anomalies and those with
respiratory, gastrointestinal, or neurological problems.
Interventions
Six trials assessed the use of nutrient-enriched versus standard for-
mula as the sole diet; one assessed formula use supplemental to
human milk (Lucas 1989b). Formulas were typically commenced
when infants were assessed as being clinically stable and able to
tolerate enteral feeds. Trial participants continued to receive the
intervention or control formula for several weeks or until they
reached a specified weight (typically about 2 kg). Most trials stip-
ulated a target volume of milk intake for both groups (typically
150 to 180 mL/kg/d).
Outcomes
Most of the trials aimed to assess effects of the intervention on
growth rates during birth hospitalisation (time to regain birth
weight and rate of gain in weight, length, or head circumference
while in hospital or until reaching a specified weight). One trial’s
primary objective was to assess effects on bone mineralization
(Kulkarni 1984). Two trials reported neurodevelopmental or long-
term growth outcomes (Lucas 1989a; Lucas 1989b). These trials
measured participants’ blood pressure and assessed insulin resis-
tance in a subset (< 20%) of the trial cohort aged 13 to 16 years.
Excluded studies
We excluded five studies following review of the full text of the
report (Atkinson 1981; Duman 2000;Haque 1987; Hering 1987;
Pridham 1999; see Characteristics of excluded studies).
Risk of bias in included studies
Quality assessments are detailed in the Characteristics of included
studies table and are illustrated in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall, we found risk of bias difficult to assess because reporting
was limited. Consequently, we scoredmost items as having unclear
risk.
Allocation
Two trial reports described methods used to ensure adequate se-
quence generation (random numbers table) and allocation con-
cealment (sealed, numbered envelopes); we assessed these trials as
being at low risk of bias (Lucas 1989a; Lucas 1989b). The other
trials did not report methods of sequence generation or allocation
concealment used (unclear risk of bias)
Blinding
One trial report described masking of study personnel and parents
or caregivers to formula types; we assessed this trial as being at low
risk of bias (Kashyap 1986). The other trial reports did not state
whether investigators or staff were masked (unclear risk of bias).
In the two trials that assessed longer-term (post infancy) growth
and neurodevelopmental outcomes, assessors were unaware of the
intervention group to which infants belonged (Lucas 1989a; Lucas
1989b).
Incomplete outcome data
Most trials reported complete follow-up for the in-hospital out-
comes assessment; we assessed them as being at low risk of attrition
bias. In three trials, infants who developed complications (5% to
10% of the total enrolled) were withdrawn from the study; there-
fore in-hospital growth data for these infants were not presented.
In the two trials that reported data for long-term outcomes, more
than 80% of participants were assessed for growth and neurode-
velopmental parameters (Lucas 1989a; Lucas 1989b). These tri-
als assessed measures of cardiovascular and metabolic health in a
subset (< 20%) of study participants aged 13 to 16 years. It is un-
clear whether or how participants were selected to undergo these
assessments.
Selective reporting
We were unable to assess reliably whether selective reporting oc-
curred as we did not have protocols or other indicators of prespec-
ified outcomes for any of the included trials.
Other potential sources of bias
The manufacturer of the formula being tested funded six tri-
als (Kashyap 1986; Kulkarni 1984; Lucas 1989a; Lucas 1989b;
Siripoonya 1989; Thom 1984). One trial did not report the source
of funding (Yesilipek 1992).
Effects of interventions
See: Summary of findings for the main comparison Nutrient-
enriched formula for preterm infants
Primary outcomes
1. Days to regain birth weight (Outcome 1.1)
Three trials reported data (Kashyap 1986; Kulkarni 1984;
Siripoonya 1989).Meta-analysis did not show an effect:MD 1.48,
95% CI -4.73 to 1.77; I² = 57% (Analysis 1.1).
2. Rate of weight gain (Outcome 1.2)
Six trials reported data (Kashyap 1986; Lucas 1989a; Lucas 1989b;
Siripoonya 1989; Thom 1984; Yesilipek 1992). Two of these trials
did not report SD values (Siripoonya 1989; Thom 1984). We
imputed these from the trials with the nearest sample size (Higgins
2017).
Meta-analysis showed that weight gain was faster among infants
fed nutrient-enriched formula: MD 2.43 g/kg/d, 95% CI 1.60 to
3.26; I² = 46% (Analysis 1.2; Figure 3).
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Figure 3. Forest plot of comparison: 1 Nutrient-enriched formula vs standard formula, outcome: 1.2 Rate of
weight gain (g/kg/d).
Kulkarni 1984 did not report numerical data but stated that there
was no difference in the average daily rate of weight gain.
3. Rate of length gain (Outcome 1.3)
Five trials reported numerical data (Kashyap 1986; Lucas 1989a;
Lucas 1989b. Siripoonya 1989; Yesilipek 1992). Siripoonya 1989
did not report SD values, so we imputed these from the trial with
the nearest sample size.
Meta-analysis did not show a statistically significant effect: MD
0.22 mm/week, 95% CI -0.70 to 1.13; I² = 67% (Analysis 1.3;
Figure 4).
Figure 4. Forest plot of comparison: 1 Nutrient-enriched formula vs standard formula, outcome: 1.3 Rate of
length gain (mm/week).
Thom 1984 did not report numerical data but stated that there
was no difference in the average daily rate of length gain.
Three trials did not report rate of length gain (Kulkarni 1984;
Lucas 1989a; Lucas 1989b).
4. Rate of head circumference gain (Outcome 1.4)
Five trials reported data (Kashyap 1986; Lucas 1989a; Lucas
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1989b; Siripoonya 1989; Yesilipek 1992). Siripoonya 1989 did
not report SD values. We imputed these from Yesilipek 1992, the
trial with the nearest sample size.
Meta-analysis showed that head circumference growth was faster
among infants fed nutrient-enriched formula: MD 1.04 mm/
week, 95% CI 0.18 to 1.89; I² = 57% (Analysis 1.4; Figure 5).
Figure 5. Forest plot of comparison: 1 Nutrient-enriched formula vs standard formula, outcome: 1.4 Rate of
head circumference gain (mm/week).
Two trials did not report rate of head circumference gain (Kulkarni
1984; Thom 1984).
5. Rate of skinfold thickness gain (Outcome 1.5 to 1.6)
Four trials reported numerical data for triceps skinfold thick-
ness gain (Kashyap 1986; Lucas 1989a; Lucas 1989b; Siripoonya
1989). Siripoonya 1989 did not report SD values. We imputed
these fromKashyap 1986. Three trials reported data for subscapu-
lar skinfold thickness gain (Kashyap 1986; Lucas 1989a; Lucas
1989b).
Infants in the nutrient-enriched formula group had statistically
significant higher rates of:
• triceps skinfold thickness gain: MD 0.12 mm/week, 95%
CI 0.07 to 0.17 (Analysis 1.5); and
• subscapular skinfold thickness gain: MD 0.10 mm/week,
95% CI 0.04 to 0.16 (Analysis 1.6).
6. Long-term growth (Outcome 1.7 to 1.16)
Two trials reported growth parameters beyond six months post
term (Lucas 1989a; Lucas 1989b).
Meta-analyses showed no statistically significant differences in av-
erage:
• weight at 18 months (MD 0.06 kg, 95% CI -0.21 to 0.33;
Analysis 1.7) or at 7.5 to 8 years post term (MD 0.30 kg, 95%
CI -0.55 to 1.15; Analysis 1.8);
• height at 18 months (MD 0.31 cm, 95% CI -0.43 to 1.06;
Analysis 1.9) or 7.5 to 8 years post term (MD 0.93 cm, 95% CI
-0.30 to 2.16; Analysis 1.10);
• head circumference at 18 months (MD 0.09 cm, 95% CI -
0.26 to 0.43; Analysis 1.11) or 7.5 to 8 years post term (MD -
0.12 cm, 95% CI -0.45 to 0.21; Analysis 1.12);
• triceps skinfold thickness at 18 months (MD 0.01 mm,
95% CI -0.42 to 0.45; Analysis 1.13) or 7.5 to 8 years post term
(MD -0.16 mm, 95% CI -0.91 to 0.60; Analysis 1.14); or
• subscapular skinfold thickness at 18 months (MD -0.14
mm, 95% CI -0.40 to 0.13; Analysis 1.15) or 7.5 to 8 years post
term (MD -0.05 mm, 95% CI -0.67 to 0.57; Analysis 1.16).
7. Neurodevelopmental outcomes (Outcome 1.17 to 1.18)
Two trials reported the number of infants with a diagnosis of
cerebral palsy when assessed at age 18 months post term follow-
up assessment (Lucas 1989a; Lucas 1989b). Meta-analysis did not
show a statistically significant difference: typical RR 0.79, 95%
CI 0.30 to 2.07; I² = 0% (Analysis 1.17).
None of the trials reported blindness or deafness as an outcome.
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Two trials reported neurodevelopmental outcomes assessed via val-
idated tools (Lucas 1989a; Lucas 1989b). Meta-analyses did not
show a difference in:
• Bayley Mental Development Index (MDI) scores at 18
months post term: MD 2.87, 95% CI -1.38 to 7.12; I² = 15%
(Analysis 1.18; Figure 6); or
Figure 6. Forest plot of comparison: 1 Nutrient-enriched formula vs standard formula, outcome: 1.18
Bayley (1) Mental Development Index at 18 months post term.
• Wechsler Revised Intelligence Scale for Children verbal,
performance, and overall scores at 7.5 to 8 years post term
(Analysis 1.19).
Meta-analysis showed a statistically significantly higher score in
the nutrient-enriched formula-fed group for:
• Bayley Psychomotor Development Index (PDI) at 18
months post term: MD 6.56, 95% CI 2.87 to 10.26; I² = 91%
(Analysis 1.18; Figure 6).
8. Necrotising enterocolitis (Outcome 1.22)
Three trials reported data (Lucas 1989a; Lucas 1989b; Thom
1984).
Meta-analysis did not show a statistically significant effect: typical
RR 0.72, 95% CI 0.41 to 1.25; I² = 18%; RD -0.01, 95% CI -
0.06 to 0.04 (Analysis 1.23).
Secondary outcomes
9. Duration of birth hospitalisation (Outcome 1.23)
One trial reported numerical data (Kulkarni 1984). There was
no statistically significant difference in duration of hospitalisation
(Analysis 1.24).
11. Feed intolerance
This outcome was not reported by any of the trials.
12. All-cause mortality (Outcome 1.24)
Two trials reported all-cause mortality (Lucas 1989a; Lucas
1989b). These trials reportedmortality until 18months post term.
Because it is likely that most mortality in this population occurred
before hospital discharge, wemade a consensus decision to include
the data.
Neither trial nor a meta-analysis showed a statistically significant
difference: typical RR 1.12, 95% CI 0.65 to 1.93; I² = 0%; RD
0.01, 95% CI -0.05 to 0.07 (Analysis 1.25).
13. Measures of body composition (Outcome 1.25 to 1.27)
Two trials reported body mass index on long-term follow-up
(Lucas 1989a; Lucas 1989b). Neither trial nor a meta-analysis
showed a statistically significant difference at:
• 18 months post term (Analysis 1.26); nor
• 7.5 to 8 years (Analysis 1.27).
Two trials reported the waist-to-hip ratio at 7.5 to 8 years. Neither
trial nor ameta-analysis showed a statistically significant difference
(Analysis 1.28).
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14. Measures of bone mineralization (Outcome 1.29 to 1.30)
Two trials reported serum alkaline phosphatase levels after four
weeks of the trial intervention (Kashyap 1986; Kulkarni 1984).
Meta-analysis did not show a statistically significant difference
(Analysis 1.29).
One trial reported bone mineral content assessed by DEXA at 8
to 12 years (Lucas 1989a). Analyses did not show any statistically
significant differences in lumbar spine, femoral neck, radius, or
whole body bone mineral content (Analysis 1.30).
15. Measures of long-term metabolic or cardiovascular
health
Two trials reported mean diastolic and systolic arterial blood pres-
sure at ages 13 to 16 years for a subset (about 20% of surviving
infants) of the trial cohort (Lucas 1989a; Lucas 1989b). The re-
port stated that there were no statistically significant differences
between groups but did not provide trial-specific data for meta-
analyses.
Two trials reported plasma glucose, insulin, and proinsulin levels
at ages 13 to 16 years for a subset (about 20%) of the trial cohort
(Lucas 1989a; Lucas 1989b). The report stated that there were
no statistically significant differences between groups but did not
provide trial-specific data for meta-analyses.
Subgroup analyses
Nutrient-enriched or standard formula as sole diet or
supplemental to human milk
Six trials compared feeding with formula as a sole diet (Kashyap
1986;Kulkarni 1984; Lucas 1989a; Siripoonya 1989;Thom1984;
Yesilipek 1992). One trial compared feeding with formula as a
supplement to breast milk (Lucas 1989b). Analyses showed sig-
nificant subgroup effects in favour of sole diet for:
• rate of head circumference gain (mm/week): test for
subgroup differences: Chi² = 4.22, df = 1 (P = 0.04), I² = 76.3%
(Analysis 1.4); and
• Bayley Psychomotor Development Index at 18 months: test
for subgroup differences: Chi² = 11.59, df = 1 (P = 0.0007), I² =
91.4% (Analysis 1.20).
Extremely preterm (< 28 weeks’ gestation) infants versus
infants born at 29 to 36 weeks’ gestation
Subgroup data were not available.
Infants with birth weight < 10th percentile for reference
population versus infants with birth weight≥ 10th percentile
Subgroup data were not available.
Sensitivity analysis
We were unable to undertake planned sensitivity analyses to de-
termine whether findings are affected by including only studies
using adequate methods (low risk of bias) as no trial fulfilled the
prespecified criteria (adequate randomisation and allocation con-
cealment, blinding of intervention and measurement, and < 10%
loss to follow-up).
D I S C U S S I O N
Summary of main results
We included seven RCTs in which a total of 590 preterm infants
participated. Meta-analyses show that infants who receive nutri-
ent-enriched formula have higher in-hospital rates of weight gain
and head growth (although not in gain in length) than infants
who receive standard formula. The effect on rate of weight gain is
similar in trials that supplied formula as a sole diet and in the trial
that supplied formula supplemental to human milk. A prespeci-
fied subgroup analysis shows that the effect on rate of head cir-
cumference growth was greater in trials that provided formula as
the sole diet than in the trial of supplemental formula use. Follow-
up of infants who participated in two of the largest trials did not
show any effects on long-term growth nor on neurodevelopmental
outcomes, with the exception of a significantly higher score for
the Bayley Psychomotor Development Index (PDI) in one trial
(Lucas 1989a).
Overall completeness and applicability of
evidence
These findings should be interpreted and applied with caution.
All trials were conducted more than 30 years ago. Most partici-
pants were stable preterm infants of low birth weight, but a few
were extremely preterm or of extremely low birth weight, limit-
ing the applicability of findings to the population at highest risk
of postnatal growth restriction secondary to suboptimal nutrient
intake. Although meta-analysis shows that nutrient-enriched for-
mula increases the in-hospital rate of weight gain, the effect size
is modest. The average daily rate of weight gain is about 2.5 g/kg
higher among infants fed nutrient-enriched versus standard for-
mula (about 75 g per month for a 1-kg infant).
Meta-analyses of growth outcomes showed moderate to high lev-
els of statistical heterogeneity that were not explained by major
differences in trial design or conduct. Participants in these trials
were similar (most were stable preterm infants). Although different
trials used a range of commercially prepared “preterm” formulas,
these contained similar levels of energy (about 80 kcal/100 mL)
and protein (> 2.0 g/100 mL) plus proportionate supplements of
minerals, vitamins, and trace elements. These levels of energy and
16Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
protein, however, are towards the lower bounds of current rec-
ommended intakes needed to match intrauterine accretion (based
on receiving about 150 mL/kg/d of milk), and this is a possible
explanation for the modest effect of the intervention on in-hos-
pital growth parameters. These findings are consistent with those
of another Cochrane Review, which showed that human milk-
fed preterm infants who received milk fortified with extra energy
and protein (to similar total levels as nutrient-enriched formula)
gained weight at about 1.8 g/kg/d faster than infants who received
unfortified breast milk (Brown 2016).
As well as uncertainty about the importance of these effects on in-
hospital growth rates, uncertainty remains about their long-term
impact on growth and development. The two trials that reported
data on outcomes beyond infancy did not show differences in
any growth parameters when assessed at 18 months and at 7.5 to
8 years. Similarly, neurodevelopmental assessments, which were
completed in more than 80% of trial participants at 18 months,
did not show evidence of effects on cognitive outcomes. Infants
who received nutrient-enriched formula as a sole diet, however,
hadhigher scores for psychomotor outcomes assessed at 18months
(Lucas 1989a). The importance of this finding is uncertain given
that the predictive value of the Bayley Scales for later development
of very preterm infants is low, with the Bayley Psychomotor Scale
explaining 12% of later motor functioning (Luttikhuizen 2013).
Meta-analysis did not indicate that feeding with nutrient-enriched
formula has important effects on the risk of necrotising enterocol-
itis. However, the risk of developing necrotising enterocolitis was
reported in only three of the seven trials, and the upper bound
of the 95% confidence interval (CI) does not exclude an increase
in risk up to 25% (Lucas 1989a; Lucas 1989b; Thom 1984). In
two trials, infants who developed necrotising enterocolitis were
excluded from ongoing participation (post randomisation) but
group-specific data were not available (Kashyap 1986; Kulkarni
1984).
A final major limitation of this review is that most included trials
were undertaken at healthcare facilities in high-income countries,
and none were conducted in community settings or in low-income
countries. Reported evidence therefore may be of limited use to
inform care practice in the resource-limited settings where most
preterm and low birth weight infants are cared for globally (Imdad
2013).
Quality of the evidence
Using GRADE methods, we assessed the quality of the evidence
as low or moderate for the prespecified outcomes (Summary of
findings for the main comparison). The trials exhibited various
weaknesses in methodological quality, specifically regarding allo-
cation concealment methods and lack of masking in most. Par-
ents, caregivers, clinicians, and investigators were likely to have
been aware of the treatment group to which infants had been allo-
cated, and this knowledge may have affected some care practices
or investigation strategies, including thresholds for other interven-
tions and investigations. Most meta-analyses showed evidence of
moderate to high heterogeneity, and pooled estimates of effect had
wide 95% CIs.
Potential biases in the review process
It is possible that our findings were subject to publication andother
reporting biases, including greater availability of numerical data
for inclusion in meta-analyses from trials that reported statistically
significant or clinically important effects. This is important given
that six of the included trials were funded or supported by manu-
facturers of the formulas being assessed (one trial did not report the
source of funding or support). Some concern exists that formula
manufacturers may selectively promote study findings from trials
of specialist formulas as part of a marketing strategy that subverts
UNICEF Baby Friendly Initiative regulations (Cleminson 2015;
WHO 2018).
We attempted tominimise the threat of publication bias by screen-
ing the reference lists of included trials and related reviews and by
searching the proceedings of themajor international perinatal con-
ferences to identify trial reports that are not yet published in full
form in academic journals. However, we cannot be sure whether
other trials have been undertaken but not reported, and concern
remains that such trials are less likely than published trials to have
detected statistically significant or clinically important effects. The
meta-analyses that we performed did not include sufficient trials
to explore symmetry of funnel plots as a means of identifying pos-
sible publication or reporting bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides low-certainty evidence that feeding preterm
infants with nutrient-enriched formula compared with standard
formula is associated with modest short-term increases in weight
gain and head growth. These short-term gains in growth do not
appear to lead to important long-term effects on growth or de-
velopment. We did not show an increase in the risk of adverse
outcomes including necrotising enterocolitis among infants who
received nutrient-enriched formula, although the total number of
infants studied was small and the data that could be abstracted
from published studies were few.
Implications for research
Given the potential for nutrient-enriched formula feeding to affect
important outcomes in preterm infants, this intervention merits
further assessment. As this practice is already widely established
and accepted in many neonatal units (particularly in high-income
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countries), it is important for researchers to determine whether
families and clinicians would support a trial of this intervention.
Trials should be powered to detect important effects on growth
rates, as well as potential adverse consequences, during infancy
and beyond. Trials should attempt to ensure that caregivers and
assessors aremasked to the intervention. Although this goal ismore
easily achievable for longer-term assessments, it is also important
for ascertainment of adverse events, such as feeding intolerance
and necrotising enterocolitis, when the threshold for investigation
or diagnosis may be affected by knowledge of the intervention.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kashyap 1986
Methods Randomised controlled trial
Participants Preterm infants of birth weight 900 to 1750 g (excluding infants with gastrointestinal
tract, renal, or respiratory problems)
Interventions Sole diet:
Nutrient-enriched formula (N = 11)
• Energy (kcal/100 mL): 82.4
• Protein (g/100 mL): 1.98
• Target intake (mL/kg/d): 180
Standard formula (N = 12)
• Energy (kcal/100 mL): 62.5
• Protein (g/100 mL): 1.26
• Target intake (mL/kg/d): 180
Outcomes Time to regain birth weight
Rate of weight, length, and head circumference gain
Rate of skinfold thickness gain - triceps and subscapular
Identification Sponsorship source: US National Institute of Health Research grants (HD13020,
AM27358, RR00645); Bristol-Myers Grant
Setting: Department of Pediatrics, Columbia University College of Physicians & Sur-
geons, USA (early 1980s)
Notes Infants were randomised into 3 groups. Only data from group 1 (“standard formula”)
and group 3 (“nutrient-enriched formula”) were included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...assigned randomly shortly after birth to receive one of
three formulas” - sequence generation not described
Allocation concealment (selection bias) Low risk Allocated colour-coded formula - investigators and
nurses did not know how the codes applied to the for-
mulas
Blinding (performance bias and detection
bias)
All outcomes
Low risk Not described
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Kashyap 1986 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Formula containers were colour coded, with code known
to neither the investigator nor nurses caring for the in-
fants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome assessments likely to include complete cohort
Selective reporting (reporting bias) Low risk A trial protocol could not be found, but data for all out-
comes described in themethods section of the paper were
reported in the results
Other bias Unclear risk The study was funded by a pharmaceutical company. It
is unclear if this company was also the manufacturer of
the formulas used in the study
Infants in the standard formula group had slightly higher
mean birth weight
Kulkarni 1984
Methods Randomised controlled trial
Participants Preterm infants of birth weight < 1501 g (excluding infants with “severe malformations,
or prolonged ventilatory assistance”). Infants were excluded post randomisation if they
failed to achieve enteral intake of 80 kcal/kg/d by 5 weeks of age and/or if they developed
necrotising enterocolitis (unclear if this was planned)
Interventions Sole diet:
Nutrient-enriched formula (N = 13)
• Energy (kcal/100 mL): 81
• Protein (g/100 mL): 2.2
• Target intake (mL/kg/d): not stated
Standard formula (N = 18)
• Energy (kcal/100 mL): 68
• Protein (g/100 mL): 1.55
• Target intake (mL/kg/d): not stated
Outcomes Time to regain birth weight
Duration of hospitalisation
Serum alkaline phosphatase level up to 14 weeks
Identification Sponsorship source: supported in part by a grant from Ross Laboraties, Columbus,
Ohio
Setting: Regional Neonatal Intensive Care Unit, Baptist Medical Center, Montgomery,
Alabama, USA (late 1970s)
Notes Infants were randomised into 3 groups. Only data from group 2 (“standard formula”)
and group 3 (“nutrient-enriched formula”) were included in this review
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Kulkarni 1984 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “... randomly allocated...”
Randomisation occurred when infants had been weaned
from supplemental oxygen and were clinically stable. No
further details provided
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome assessments likely to include complete cohort
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Funded by Ross Laboratories, the manufacturer of the
formula milks used (Osomil and Similac). An employee
of Ross Laboratories is acknowledged for having provided
“help in statistical data analyses”
Lucas 1989a
Methods Randomised controlled trial
Participants Preterm infants weighing < 1850 g at birth (excluding those with “major congenital
malformations known to impair growth and development”)
Interventions Sole diet:
Nutrient-enriched formula (N = 81)
• Energy (kcal/100 mL): 80
• Protein (g/100 mL): 2.0
• Target intake (mL/kg/d): 180
Standard formula (N = 79)
• Energy (kcal/100 mL): 68
• Protein (g/100 mL): 1.45
• Target intake (mL/kg/d): 180
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Lucas 1989a (Continued)
Outcomes Rates of change in weight and head circumference (135/160 infants) from the point
of regained birth weight until discharge from the neonatal unit or reaching a weight of
2000 g
Necrotising enterocolitis - suspected and confirmed reported for complete cohort of 160
infants
Bayley Mental Development Index and Psychomotor Development Index at 18 months
post term in 114/141 surviving infants
Growth parameters in surviving infants (weight, length, and head circumference) at 18
months (119 infants) and at 7.5 to 8 years (135 infants) post term
Intelligence quotient at (IQ) at 7.5 to 8 years with abbreviated Weschler Intelligence
Scale for Children (revised Anglicised version: WISC-R UK)
Bone mineral content (DEXA) at 8 to 12 years
Blood pressure and plasma glucose and split proinsulin levels assessed in 31 of 141 (22%)
surviving infants at 13 to 16 years
Identification Sponsorship source: Farley Health Products gave financial assistance, continued collab-
oration, and supply of trial diets
Setting: Norfolk and Norwich Hospital, Norwich Special Care Baby Unit and Jessop
Hospital, Sheffield, UK (early 1980s)
Notes Investigators reported a parallel trial of the same interventions used as a supplement to
human milk (as opposed to use as the sole diet) - see Lucas 1989b
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Assignments were based on permuted blocks of variable
length”
Stratified by birth weight < 1201 g and 1201 to 1850 g
Randomised within first 48 hours after birth
Randomisation was conducted independently at each
centre
Allocation concealment (selection bias) Low risk “... sealed envelopes...”; “...consecutively-numbered”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Formulas were identified by numerical code so that
neonatal staff, parents, and eventually follow-up staff
were blinded to dietary assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Long-term growth and developmental assessments were
completed for > 80% of surviving infants
Cardiovascular (blood pressure) and metabolic (plasma
insulin levels) assessments at age 15 years available for <
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Lucas 1989a (Continued)
25% enrolled participants
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Farley Health Products, the manufacturer of the formula
milks used in this trial, was acknowledged “for their fi-
nancial assistance, continuing collaboration, and supply
of trial diets.” It is unclear how far the manufacturer was
involved in the conduct of the trial, the statistical analy-
ses, and preparation of the published report
Lucas 1989b
Methods Randomised controlled trial
Participants Preterm infants weighing < 1850 g at birth (excluding those with “major congenital
malformations known to impair growth and development”)
Interventions Supplemental to human milk:
Nutrient-enriched formula (N = 132)
• Energy (kcal/100 mL): 80
• Protein (g/100 mL): 2.0
• Target intake (mL/kg/d): 180
Standard formula (N = 132)
• Energy (kcal/100 mL): 68
• Protein (g/100 mL): 1.45
• Target intake (mL/kg/d): 180
Outcomes Rates of change in weight and head circumference (225/264 infants) from the point
of regained birth weight until discharge from the neonatal unit or reaching a weight of
2000 g
Necrotising enterocolitis - suspected and confirmed reported for complete cohort of 264
infants
Bayley Mental Development Index and Psychomotor Development Index at 18 months
post term in 196/236 surviving infants
Growth parameters in surviving infants (weight, length, and head circumference) at 18
months (225 infants) and at 7.5 to 8 years (224 infants) post term
Bone mineral content (DEXA) at 8 to 12 years
Blood pressure and plasma glucose and split proinsulin levels assessed in 55 of 235
(218%) surviving infants at 13 to 16 years
Identification Sponsorship source: Farley Health Products gave financial assistance, continued collab-
oration, and supply of trial diets
Setting: Norfolk and Norwich Hospital, Norwich Special Care Baby Unit and Jessop
Hospital, Sheffield, UK (early 1980s)
Notes Investigators reported a parallel trial of the same interventions used as the sole diet (as
opposed to use as a supplement to human milk) - see Lucas 1989a
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Lucas 1989b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Assignments were based on permuted blocks of variable
length”
Stratified by birth weight < 1201 g and 1201 to 1850 g
Allocation concealment (selection bias) Low risk “... sealed envelopes...”; “...consecutively-numbered”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Long-term growth and developmental assessments were
completed for > 80% of surviving infants
Cardiovascular (blood pressure) and metabolic (plasma
insulin levels) assessments at age 15 years available for <
25% of enrolled participants
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Farley Health Products, the manufacturer of the formula
milks used in this trial, was acknowledged “for their fi-
nancial assistance, continuing collaboration, and supply
of trial diets.” It is unclear how far the manufacturer was
involved in the conduct of the trial, the statistical analy-
ses, and preparation of the published report
Siripoonya 1989
Methods Randomised controlled trial
Participants Preterm infants weighing 1000 to 1750 g at birth (excluding those with “respiratory
distress, infection and other pathology that affected growth and feeding”)
Interventions Sole diet:
Nutrient-enriched formula (N = 13)
• Energy (kcal/100 mL): 80
• Protein (g/100 mL): 2.3
• Target intake (mL/kg/d): 150
Standard formula (N = 12)
• Energy (kcal/100 mL): 67
• Protein (g/100 mL): 1.23
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Siripoonya 1989 (Continued)
• Target intake (mL/kg/d): 150
Outcomes Time to regain birth weight and rate of weight gain - calculated from daily weights to
the nearest 10 g
Rate of length gain and fronto-occipital head circumference measured weekly to the
nearest mm
Identification Sponsorship source: supported in part by a grant from Nestle, Switzerland
Setting: Department of Paediatrics, Mahidol University, Thailand (early-mid 1980s)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 31 preterm infants who were randomised, 6 were ex-
cluded due to “illness or infection”. No outcome data
were reported for these infants, and it is not stated to
which group the excluded infants belonged
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Nestle, the manufacturer of the formula milks used in
this trial, was the main sponsor
Thom 1984
Methods Randomised controlled trial
Participants “Healthy” newborn infants of birth weight < 1501 g
Interventions Sole diet:
Nutrient-enriched formula (N = 35)
• Energy (kcal/100 mL): 80
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Thom 1984 (Continued)
• Protein (g/100 mL): 2.2
• Target intake (mL/kg/d): not stated
Standard formula (N = 30)
• Energy (kcal/100 mL): 67
• Protein (g/100 mL): 1.23
• Target intake (mL/kg/d): not stated
Outcomes Time to regain birth weight
Rate of weight, length, and head circumference gain
Identification Sponsorship source: Nestle Infant and Dietetic Services acknowledged for providing
“financial assistance”. Further details of sponsorship sources not reported
Setting: Department of Paediatrics, University of Stellenbosch and Tygerberg Hospital,
South Africa (early 1980s)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “... randomly allocated” - sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 75 randomised infants, 41 were available for assess-
ment at 28 days old
Selective reporting (reporting bias) High risk Numerical data not reported for growth outcomes (find-
ings described as “not statistically significant”)
Other bias High risk The trial was undertaken explicitly to “evaluate this for-
mula [Alprem] clinically”. Nestle, the manufacturer of
Alprem, is acknowledged for the “supply of Alprem and
for financial assistance”. It is unclear how the comparator
formula (Nan, also manufactured by Nestle) was sourced
and how far the manufacturer was involved in the con-
duct of the trial, the statistical analyses, or production of
the publication
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Yesilipek 1992
Methods Randomised controlled trial
Participants Preterm infants weighing < 2000 g at birth (excluding those with “congenital malforma-
tions, infections or respiratory distress syndrome”)
Interventions Sole diet:
Nutrient-enriched formula (N = 11)
• Energy (kcal/100 mL): 81
• Protein (g/100 mL): 1.92
• Target intake (mL/kg/d): 150
Standard formula (N = 11)
• Energy (kcal/100 mL): 67
• Protein (g/100 mL): 1.5
• Target intake (mL/kg/d): 150
Outcomes Rate of weight, length, and head circumference gain
Identification Sponsorship source: not stated
Setting: Maternity and Children’s Hospital, Samsun, Turkey (late 1980s)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomly divided...” - sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome assessments likely to include complete cohort
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Funding source not stated
DEXA: dual-energy X-ray absorptiometry.
IQ: intelligence quotient.
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WISC-R: Wechsler Intelligence Scale for Children - Revised.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Atkinson 1981 Not an RCT
Duman 2000 Unclear if RCT; none of the formulas used met the definition of “standard”
Haque 1987 Not an RCT
Hering 1987 Intervention formula used did not meet the definition of “nutrient enriched”
Pridham 1999 Term-equivalent infants randomly allocated to nutrient-enriched vs standard formula when nipple-feeding estab-
lished (> 36 weeks’ postmenstrual age)
Yin 2004 Term infants (growth restricted)
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Costa 1996
Methods Quasi-RCT (birth order alternating allocation to either group)
Participants Preterm infants (< 37 weeks’ gestation) with birth weight < 1750 g (excluding those with serious congenital anomalies,
surgical diseases of the gastrointestinal tract, congential infection, and home birth)
Subsequent exclusion criteria: change in diet due to team failure; maternal refusal to keep up the regimen up to 40
weeks
Interventions Supplemental to human milk:
Nutrient-enriched formula (N = 29: 15 average for gestational age; 14 small for gestational age)
• Energy (kcal/100 mL): 81
• Protein (g/100 mL): value not given
• Target intake (mL/kg/d): 200
Standard formula (N = 41: 20 average for gestational age; 21 small for gestational age)
• Energy (kcal/100 mL): 67
• Protein (g/100 mL): 1.23
• Target intake (mL/kg/d): 200
Outcomes Time to regain birth weight
Rate of weight gain
Length gain
Head circumference gain
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Costa 1996 (Continued)
Feed intolerance
Notes Awaiting translation and clarification about intervention formula protein content
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D A T A A N D A N A L Y S E S
Comparison 1. Nutrient-enriched formula vs standard formula
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to regain birth weight 3 74 Mean Difference (IV, Fixed, 95% CI) -1.48 [-4.73, 1.77]
2 Rate of weight gain (g/kg/d) 6 440 Mean Difference (IV, Fixed, 95% CI) 2.43 [1.60, 3.26]
2.1 Sole diet 5 225 Mean Difference (IV, Fixed, 95% CI) 3.87 [2.26, 5.47]
2.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) 1.90 [0.93, 2.87]
3 Rate of length gain (mm/week) 5 386 Mean Difference (IV, Fixed, 95% CI) 0.22 [-0.70, 1.13]
3.1 Sole diet 4 185 Mean Difference (IV, Fixed, 95% CI) 1.72 [0.23, 3.20]
3.2 Supplemental to human
milk
1 201 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.86, 0.46]
4 Rate of head circumference gain
(mm/week)
5 399 Mean Difference (IV, Fixed, 95% CI) 1.04 [0.18, 1.89]
4.1 Sole diet 4 184 Mean Difference (IV, Fixed, 95% CI) 2.26 [1.00, 3.52]
4.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.16, 1.16]
5 Rate of skinfold thickness gain -
triceps (mm/week)
4 364 Mean Difference (IV, Fixed, 95% CI) 0.12 [0.07, 0.17]
5.1 Sole diet 3 163 Mean Difference (IV, Fixed, 95% CI) 0.16 [0.05, 0.27]
5.2 Supplemental to human
milk
1 201 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.05, 0.17]
6 Rate of skinfold thickness gain -
subscapular (mm/week)
3 339 Mean Difference (IV, Fixed, 95% CI) 0.10 [0.04, 0.16]
6.1 Sole diet 2 138 Mean Difference (IV, Fixed, 95% CI) 0.15 [0.07, 0.24]
6.2 Supplemental to human
milk
1 201 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.02, 0.14]
7 Weight (kg) at 18 months post
term
2 334 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.21, 0.33]
7.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.31, 0.71]
7.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.32, 0.32]
8 Weight (kg) at 7.5 to 8 years
post term
2 359 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.55, 1.15]
8.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.99, 1.59]
8.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.84, 1.44]
9 Height (cm) at 18 months post
term
2 334 Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.43, 1.06]
9.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) 1.20 [-0.26, 2.66]
9.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.87, 0.87]
10 Height (cm) at 7.5 to 8 years
post term
2 359 Mean Difference (IV, Fixed, 95% CI) 0.93 [-0.30, 2.16]
10.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.69, 3.29]
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10.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.86, 2.26]
11 Head circumference (cm) at 18
months post term
2 334 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.26, 0.43]
11.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.32, 0.72]
11.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.45, 0.45]
12 Head circumference (cm) at
7.5 to 8 years post term
2 359 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.45, 0.21]
12.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.52, 0.52]
12.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.62, 0.22]
13 Triceps skinfold thickness
(mm) at 18 months post term
2 334 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.42, 0.45]
13.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.50, 0.90]
13.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.65, 0.45]
14 Triceps skinfold thickness
(mm) at 7.5 to 8 years post
term
2 359 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.91, 0.60]
14.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.85, 1.45]
14.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.50, 0.50]
15 Subscapular skinfold thickness
(mm) at 18 months post term
2 334 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.40, 0.13]
15.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.47, 0.47]
15.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.52, 0.12]
16 Subscapular skinfold thickness
(mm) at 7.5 to 8 years post
term
2 359 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.67, 0.57]
16.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.96, 0.76]
16.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.90, 0.90]
17 Cerebral palsy at 18 months
post term
2 377 Risk Ratio (IV, Fixed, 95% CI) 0.79 [0.30, 2.07]
17.1 Sole diet 1 141 Risk Ratio (IV, Fixed, 95% CI) 0.51 [0.05, 5.47]
17.2 Supplemental to human
milk
1 236 Risk Ratio (IV, Fixed, 95% CI) 0.86 [0.30, 2.47]
18 Bayley (1)Mental Development
Index at 18 months post term
2 310 Mean Difference (IV, Fixed, 95% CI) 2.81 [-1.44, 7.06]
18.1 Sole diet 1 114 Mean Difference (IV, Fixed, 95% CI) 6.0 [-1.07, 13.07]
18.2 Supplemental to human
milk
1 196 Mean Difference (IV, Fixed, 95% CI) 1.0 [-4.32, 6.32]
19 Weschler Verbal Intelligence
Quotient at 7.5 to 8 years post
term
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 Sole diet 1 133 Mean Difference (IV, Fixed, 95% CI) 4.90 [-0.38, 10.18]
19.2 Supplemental to human
milk
1 222 Mean Difference (IV, Fixed, 95% CI) 0.30 [-4.41, 5.01]
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20 Bayley (1) Psychomotor
Development Index at 18
months post term
2 310 Mean Difference (IV, Fixed, 95% CI) 6.56 [2.87, 10.26]
20.1 Sole diet 1 114 Mean Difference (IV, Fixed, 95% CI) 14.70 [8.73, 20.67]
20.2 Supplemental to human
milk
1 196 Mean Difference (IV, Fixed, 95% CI) 1.5 [-3.20, 6.20]
21 Weschler Performance
Intelligence Quotient at 7.5 to
8 years post term
2 355 Mean Difference (IV, Fixed, 95% CI) 0.06 [-3.24, 3.36]
21.1 Sole diet 1 133 Mean Difference (IV, Fixed, 95% CI) -1.70 [-7.12, 3.72]
21.2 Supplemental to human
milk
1 222 Mean Difference (IV, Fixed, 95% CI) 1.10 [-3.06, 5.26]
22 Weschler Overall Intelligence
Quotient at 7.5 to 8 years post
term
2 355 Mean Difference (IV, Fixed, 95% CI) 1.49 [-1.61, 4.59]
22.1 Sole diet 1 133 Mean Difference (IV, Fixed, 95% CI) 2.20 [-2.65, 7.05]
22.2 Supplemental to human
milk
1 222 Mean Difference (IV, Fixed, 95% CI) 1.0 [-3.03, 5.03]
23 Necrotising enterocolitis 3 489 Risk Ratio (IV, Fixed, 95% CI) 0.72 [0.41, 1.25]
23.1 Sole diet 2 225 Risk Ratio (IV, Fixed, 95% CI) 0.67 [0.27, 1.65]
23.2 Supplemental to human
milk
1 264 Risk Ratio (IV, Fixed, 95% CI) 0.75 [0.37, 1.52]
24 Duration of birth
hospitalisation
1 31 Mean Difference (IV, Fixed, 95% CI) 1.0 [-8.81, 10.81]
25 All-cause mortality 2 424 Risk Ratio (IV, Fixed, 95% CI) 1.12 [0.65, 1.93]
25.1 Sole diet 1 160 Risk Ratio (IV, Fixed, 95% CI) 1.34 [0.57, 3.16]
25.2 Supplemental to human
milk
1 264 Risk Ratio (IV, Fixed, 95% CI) 1.0 [0.50, 2.01]
26 Body mass index (kg/m²) at 18
months post term
2 334 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.43, 0.23]
26.1 Sole diet 1 119 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.70, 0.50]
26.2 Supplemental to human
milk
1 215 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.50, 0.30]
27 Body mass index (kg/m²) at 7.5
to 8 years post term
2 359 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.33, 0.44]
27.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.57, 0.57]
27.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.41, 0.61]
28 Waist-to-hip ratio at 7.5 to 8
years post term
2 359 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.16, 0.12]
28.1 Sole diet 1 135 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.20, 0.14]
28.2 Supplemental to human
milk
1 224 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.26, 0.28]
29 Serum alkaline phosphatase
level after 4 weeks (IU/mL)
2 49 Mean Difference (IV, Fixed, 95% CI) -41.12 [-86.89, 4.
65]
30 Bone mineral content (g)
assessed by DEXA at 8 to 12
years
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
30.1 Lumbar spine 1 61 Mean Difference (IV, Fixed, 95% CI) -2.70 [-5.62, 0.22]
30.2 Femoral neck 1 61 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.19, 0.39]
30.3 Radius 1 57 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.08, 0.02]
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30.4 Whole body 1 60 Mean Difference (IV, Fixed, 95% CI) -77.0 [-777.29, 623.
29]
Analysis 1.1. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 1 Time to regain
birth weight.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 1 Time to regain birth weight
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kashyap 1986 9 15.9 (9.2) 9 17.7 (3.7) 25.1 % -1.80 [ -8.28, 4.68 ]
Kulkarni 1984 13 13 (10.8) 18 9 (4.2) 27.6 % 4.00 [ -2.18, 10.18 ]
Siripoonya 1989 13 13.5 (5.8) 12 18 (6.2) 47.4 % -4.50 [ -9.22, 0.22 ]
Total (95% CI) 35 39 100.0 % -1.48 [ -4.73, 1.77 ]
Heterogeneity: Chi2 = 4.60, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Standard formula Favours Nutrient-enriched formula
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Analysis 1.2. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 2 Rate of weight gain
(g/kg/d).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 2 Rate of weight gain (g/kg/d)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Kashyap 1986 9 22 (9.3) 9 13.9 (8.4) 1.0 % 8.10 [ -0.09, 16.29 ]
Lucas 1989a 61 16.6 (3.9) 58 13 (5.9) 21.3 % 3.60 [ 1.79, 5.41 ]
Siripoonya 1989 13 9.1 (10.4) 12 3.6 (8.2) 1.3 % 5.50 [ -1.81, 12.81 ]
Thom 1984 21 13.2 (10.4) 20 12.9 (8.2) 2.1 % 0.30 [ -5.42, 6.02 ]
Yesilipek 1992 11 25.7 (10.4) 11 15.9 (8.2) 1.1 % 9.80 [ 1.97, 17.63 ]
Subtotal (95% CI) 115 110 26.9 % 3.87 [ 2.26, 5.47 ]
Heterogeneity: Chi2 = 5.00, df = 4 (P = 0.29); I2 =20%
Test for overall effect: Z = 4.71 (P < 0.00001)
2 Supplemental to human milk
Lucas 1989b 105 15.3 (4.1) 110 13.4 (3.1) 73.1 % 1.90 [ 0.93, 2.87 ]
Subtotal (95% CI) 105 110 73.1 % 1.90 [ 0.93, 2.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.82 (P = 0.00013)
Total (95% CI) 220 220 100.0 % 2.43 [ 1.60, 3.26 ]
Heterogeneity: Chi2 = 9.21, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 5.71 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.20, df = 1 (P = 0.04), I2 =76%
-10 -5 0 5 10
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Analysis 1.3. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 3 Rate of length gain
(mm/week).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 3 Rate of length gain (mm/week)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Kashyap 1986 9 12.4 (9) 9 9.4 (5.7) 1.7 % 3.00 [ -3.96, 9.96 ]
Lucas 1989a 61 10.5 (5.6) 59 9.1 (4.9) 23.7 % 1.40 [ -0.48, 3.28 ]
Siripoonya 1989 13 8 (5.3) 12 8.7 (3.6) 6.7 % -0.70 [ -4.23, 2.83 ]
Yesilipek 1992 11 16.3 (5.3) 11 10.9 (3.6) 5.8 % 5.40 [ 1.61, 9.19 ]
Subtotal (95% CI) 94 91 38.0 % 1.72 [ 0.23, 3.20 ]
Heterogeneity: Chi2 = 5.68, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Supplemental to human milk
Lucas 1989b 103 9.1 (4.2) 98 9.8 (4.2) 62.0 % -0.70 [ -1.86, 0.46 ]
Subtotal (95% CI) 103 98 62.0 % -0.70 [ -1.86, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 197 189 100.0 % 0.22 [ -0.70, 1.13 ]
Heterogeneity: Chi2 = 11.99, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 6.31, df = 1 (P = 0.01), I2 =84%
-4 -2 0 2 4
Favours Standard formula Favours Nutrient-enriched formula
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Analysis 1.4. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 4 Rate of head
circumference gain (mm/week).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 4 Rate of head circumference gain (mm/week)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Kashyap 1986 9 11.7 (8.6) 9 8.5 (4.5) 1.8 % 3.20 [ -3.14, 9.54 ]
Lucas 1989a 61 10.7 (4.4) 58 8.5 (5.3) 23.7 % 2.20 [ 0.45, 3.95 ]
Siripoonya 1989 13 7.2 (3.6) 12 6.4 (3) 10.9 % 0.80 [ -1.79, 3.39 ]
Yesilipek 1992 11 11.9 (3.6) 11 8 (3) 9.5 % 3.90 [ 1.13, 6.67 ]
Subtotal (95% CI) 94 90 46.0 % 2.26 [ 1.00, 3.52 ]
Heterogeneity: Chi2 = 2.66, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00044)
2 Supplemental to human milk
Lucas 1989b 105 9.7 (4.3) 110 9.7 (4.4) 54.0 % 0.0 [ -1.16, 1.16 ]
Subtotal (95% CI) 105 110 54.0 % 0.0 [ -1.16, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 199 200 100.0 % 1.04 [ 0.18, 1.89 ]
Heterogeneity: Chi2 = 9.33, df = 4 (P = 0.05); I2 =57%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 6.67, df = 1 (P = 0.01), I2 =85%
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Analysis 1.5. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 5 Rate of skinfold
thickness gain - triceps (mm/week).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 5 Rate of skinfold thickness gain - triceps (mm/week)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Kashyap 1986 9 0.67 (1.02) 9 0.32 (0.42) 0.5 % 0.35 [ -0.37, 1.07 ]
Lucas 1989a 61 0.41 (0.28) 59 0.26 (0.35) 19.9 % 0.15 [ 0.04, 0.26 ]
Siripoonya 1989 13 0.31 (1.02) 12 0.07 (0.42) 0.7 % 0.24 [ -0.36, 0.84 ]
Subtotal (95% CI) 83 80 21.1 % 0.16 [ 0.05, 0.27 ]
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Supplemental to human milk
Lucas 1989b 103 0.36 (0.07) 98 0.25 (0.28) 78.9 % 0.11 [ 0.05, 0.17 ]
Subtotal (95% CI) 103 98 78.9 % 0.11 [ 0.05, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
Total (95% CI) 186 178 100.0 % 0.12 [ 0.07, 0.17 ]
Heterogeneity: Chi2 = 0.93, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
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Analysis 1.6. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 6 Rate of skinfold
thickness gain - subscapular (mm/week).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 6 Rate of skinfold thickness gain - subscapular (mm/week)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Kashyap 1986 9 0.64 (0.78) 9 0.32 (0.6) 0.8 % 0.32 [ -0.32, 0.96 ]
Lucas 1989a 61 0.4 (0.28) 59 0.25 (0.21) 44.3 % 0.15 [ 0.06, 0.24 ]
Subtotal (95% CI) 70 68 45.1 % 0.15 [ 0.07, 0.24 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00061)
2 Supplemental to human milk
Lucas 1989b 103 0.39 (0.35) 98 0.33 (0.21) 54.9 % 0.06 [ -0.02, 0.14 ]
Subtotal (95% CI) 103 98 54.9 % 0.06 [ -0.02, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 173 166 100.0 % 0.10 [ 0.04, 0.16 ]
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =25%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Chi2 = 2.39, df = 1 (P = 0.12), I2 =58%
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Analysis 1.7. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 7 Weight (kg) at 18
months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 7 Weight (kg) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 10.4 (1.6) 58 10.2 (1.2) 28.6 % 0.20 [ -0.31, 0.71 ]
Subtotal (95% CI) 61 58 28.6 % 0.20 [ -0.31, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 Supplemental to human milk
Lucas 1989b 105 10.3 (1.2) 110 10.3 (1.2) 71.4 % 0.0 [ -0.32, 0.32 ]
Subtotal (95% CI) 105 110 71.4 % 0.0 [ -0.32, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 166 168 100.0 % 0.06 [ -0.21, 0.33 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.8. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 8 Weight (kg) at 7.5
to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 8 Weight (kg) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 23.3 (3.5) 68 23 (4.1) 44.0 % 0.30 [ -0.99, 1.59 ]
Subtotal (95% CI) 67 68 44.0 % 0.30 [ -0.99, 1.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 Supplemental to human milk
Lucas 1989b 111 23.8 (4.3) 113 23.5 (4.4) 56.0 % 0.30 [ -0.84, 1.44 ]
Subtotal (95% CI) 111 113 56.0 % 0.30 [ -0.84, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.61)
Total (95% CI) 178 181 100.0 % 0.30 [ -0.55, 1.15 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 1.9. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 9 Height (cm) at 18
months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 9 Height (cm) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 80.9 (4.5) 58 79.7 (3.6) 26.2 % 1.20 [ -0.26, 2.66 ]
Subtotal (95% CI) 61 58 26.2 % 1.20 [ -0.26, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 Supplemental to human milk
Lucas 1989b 105 80 (3) 110 80 (3.5) 73.8 % 0.0 [ -0.87, 0.87 ]
Subtotal (95% CI) 105 110 73.8 % 0.0 [ -0.87, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 166 168 100.0 % 0.31 [ -0.43, 1.06 ]
Heterogeneity: Chi2 = 1.91, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 1.91, df = 1 (P = 0.17), I2 =48%
-2 -1 0 1 2
Favours Standard formula Favours Nutrient-enriched formula
44Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 10 Height (cm) at
7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 10 Height (cm) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 122.9 (5.5) 68 121.6 (6.3) 37.9 % 1.30 [ -0.69, 3.29 ]
Subtotal (95% CI) 67 68 37.9 % 1.30 [ -0.69, 3.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 Supplemental to human milk
Lucas 1989b 111 123.2 (5.9) 113 122.5 (6) 62.1 % 0.70 [ -0.86, 2.26 ]
Subtotal (95% CI) 111 113 62.1 % 0.70 [ -0.86, 2.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 178 181 100.0 % 0.93 [ -0.30, 2.16 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 1.11. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 11 Head
circumference (cm) at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 11 Head circumference (cm) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 47.7 (1.5) 58 47.5 (1.4) 43.2 % 0.20 [ -0.32, 0.72 ]
Subtotal (95% CI) 61 58 43.2 % 0.20 [ -0.32, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Supplemental to human milk
Lucas 1989b 105 48.1 (1.6) 110 48.1 (1.8) 56.8 % 0.0 [ -0.45, 0.45 ]
Subtotal (95% CI) 105 110 56.8 % 0.0 [ -0.45, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 166 168 100.0 % 0.09 [ -0.26, 0.43 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 1.12. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 12 Head
circumference (cm) at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 12 Head circumference (cm) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 52.1 (1.5) 68 52.1 (1.6) 39.2 % 0.0 [ -0.52, 0.52 ]
Subtotal (95% CI) 67 68 39.2 % 0.0 [ -0.52, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Supplemental to human milk
Lucas 1989b 111 52.5 (1.7) 113 52.7 (1.5) 60.8 % -0.20 [ -0.62, 0.22 ]
Subtotal (95% CI) 111 113 60.8 % -0.20 [ -0.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 178 181 100.0 % -0.12 [ -0.45, 0.21 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 1.13. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 13 Triceps skinfold
thickness (mm) at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 13 Triceps skinfold thickness (mm) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 8.4 (2.1) 58 8.2 (1.8) 38.1 % 0.20 [ -0.50, 0.90 ]
Subtotal (95% CI) 61 58 38.1 % 0.20 [ -0.50, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Supplemental to human milk
Lucas 1989b 105 8.1 (2.2) 110 8.2 (1.9) 61.9 % -0.10 [ -0.65, 0.45 ]
Subtotal (95% CI) 105 110 61.9 % -0.10 [ -0.65, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 166 168 100.0 % 0.01 [ -0.42, 0.45 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.14. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 14 Triceps skinfold
thickness (mm) at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 14 Triceps skinfold thickness (mm) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 9.9 (3.5) 68 9.6 (3.3) 42.9 % 0.30 [ -0.85, 1.45 ]
Subtotal (95% CI) 67 68 42.9 % 0.30 [ -0.85, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Supplemental to human milk
Lucas 1989b 111 9.6 (3.9) 113 10.1 (3.7) 57.1 % -0.50 [ -1.50, 0.50 ]
Subtotal (95% CI) 111 113 57.1 % -0.50 [ -1.50, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 178 181 100.0 % -0.16 [ -0.91, 0.60 ]
Heterogeneity: Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
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Analysis 1.15. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 15 Subscapular
skinfold thickness (mm) at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 15 Subscapular skinfold thickness (mm) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 5.7 (1.3) 58 5.7 (1.3) 32.0 % 0.0 [ -0.47, 0.47 ]
Subtotal (95% CI) 61 58 32.0 % 0.0 [ -0.47, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Supplemental to human milk
Lucas 1989b 105 5.4 (1.2) 110 5.6 (1.2) 68.0 % -0.20 [ -0.52, 0.12 ]
Subtotal (95% CI) 105 110 68.0 % -0.20 [ -0.52, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 166 168 100.0 % -0.14 [ -0.40, 0.13 ]
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 1.16. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 16 Subscapular
skinfold thickness (mm) at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 16 Subscapular skinfold thickness (mm) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 6.3 (2.4) 68 6.4 (2.7) 52.3 % -0.10 [ -0.96, 0.76 ]
Subtotal (95% CI) 67 68 52.3 % -0.10 [ -0.96, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Supplemental to human milk
Lucas 1989b 111 6.4 (3.9) 113 6.4 (2.9) 47.7 % 0.0 [ -0.90, 0.90 ]
Subtotal (95% CI) 111 113 47.7 % 0.0 [ -0.90, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 178 181 100.0 % -0.05 [ -0.67, 0.57 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 1.17. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 17 Cerebral palsy at
18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 17 Cerebral palsy at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 1/70 2/71 16.6 % 0.51 [ 0.05, 5.47 ]
Subtotal (95% CI) 70 71 16.6 % 0.51 [ 0.05, 5.47 ]
Total events: 1 (Nutrient-enriched formula), 2 (Standard formula)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Supplemental to human milk
Lucas 1989b 6/118 7/118 83.4 % 0.86 [ 0.30, 2.47 ]
Subtotal (95% CI) 118 118 83.4 % 0.86 [ 0.30, 2.47 ]
Total events: 6 (Nutrient-enriched formula), 7 (Standard formula)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 188 189 100.0 % 0.79 [ 0.30, 2.07 ]
Total events: 7 (Nutrient-enriched formula), 9 (Standard formula)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 1.18. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 18 Bayley (1)
Mental Development Index at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 18 Bayley (1) Mental Development Index at 18 months post term
Study or subgroup Standard formula
Nutrient-
enriched
formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 59 98.6 (18.4) 55 92.6 (20) 36.2 % 6.00 [ -1.07, 13.07 ]
Subtotal (95% CI) 59 55 36.2 % 6.00 [ -1.07, 13.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
2 Supplemental to human milk
Lucas 1989b 95 104.5 (19) 101 103.5 (19) 63.8 % 1.00 [ -4.32, 6.32 ]
Subtotal (95% CI) 95 101 63.8 % 1.00 [ -4.32, 6.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 154 156 100.0 % 2.81 [ -1.44, 7.06 ]
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =18%
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Analysis 1.19. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 19 Weschler Verbal
Intelligence Quotient at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 19 Weschler Verbal Intelligence Quotient at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 66 97.6 (14.6) 67 92.7 (16.4) 100.0 % 4.90 [ -0.38, 10.18 ]
Subtotal (95% CI) 66 67 100.0 % 4.90 [ -0.38, 10.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Supplemental to human milk
Lucas 1989b 110 103 (17.8) 112 102.7 (18) 100.0 % 0.30 [ -4.41, 5.01 ]
Subtotal (95% CI) 110 112 100.0 % 0.30 [ -4.41, 5.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =38%
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Analysis 1.20. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 20 Bayley (1)
Psychomotor Development Index at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 20 Bayley (1) Psychomotor Development Index at 18 months post term
Study or subgroup Standard formula
Nutrient-
enriched
formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 59 98.9 (16.9) 55 84.2 (15.6) 38.3 % 14.70 [ 8.73, 20.67 ]
Subtotal (95% CI) 59 55 38.3 % 14.70 [ 8.73, 20.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.83 (P < 0.00001)
2 Supplemental to human milk
Lucas 1989b 95 94 (16.6) 101 92.5 (17) 61.7 % 1.50 [ -3.20, 6.20 ]
Subtotal (95% CI) 95 101 61.7 % 1.50 [ -3.20, 6.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Total (95% CI) 154 156 100.0 % 6.56 [ 2.87, 10.26 ]
Heterogeneity: Chi2 = 11.59, df = 1 (P = 0.00066); I2 =91%
Test for overall effect: Z = 3.48 (P = 0.00050)
Test for subgroup differences: Chi2 = 11.59, df = 1 (P = 0.00), I2 =91%
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Analysis 1.21. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 21 Weschler
Performance Intelligence Quotient at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 21 Weschler Performance Intelligence Quotient at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 66 96 (17.1) 67 97.7 (14.7) 37.0 % -1.70 [ -7.12, 3.72 ]
Subtotal (95% CI) 66 67 37.0 % -1.70 [ -7.12, 3.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Supplemental to human milk
Lucas 1989b 110 105.1 (15.7) 112 104 (15.9) 63.0 % 1.10 [ -3.06, 5.26 ]
Subtotal (95% CI) 110 112 63.0 % 1.10 [ -3.06, 5.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 176 179 100.0 % 0.06 [ -3.24, 3.36 ]
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 1.22. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 22 Weschler
Overall Intelligence Quotient at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 22 Weschler Overall Intelligence Quotient at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 66 97 (14.6) 67 94.8 (13.9) 40.8 % 2.20 [ -2.65, 7.05 ]
Subtotal (95% CI) 66 67 40.8 % 2.20 [ -2.65, 7.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 Supplemental to human milk
Lucas 1989b 110 104.2 (14.7) 112 103.2 (15.9) 59.2 % 1.00 [ -3.03, 5.03 ]
Subtotal (95% CI) 110 112 59.2 % 1.00 [ -3.03, 5.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 176 179 100.0 % 1.49 [ -1.61, 4.59 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 1.23. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 23 Necrotising
enterocolitis.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 23 Necrotising enterocolitis
Study or subgroup
Nutrient-
enriched
formula Standard formula Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 6/81 11/79 34.7 % 0.53 [ 0.21, 1.37 ]
Thom 1984 3/35 0/30 3.6 % 6.03 [ 0.32, 112.21 ]
Subtotal (95% CI) 116 109 38.3 % 0.67 [ 0.27, 1.65 ]
Total events: 9 (Nutrient-enriched formula), 11 (Standard formula)
Heterogeneity: Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.87 (P = 0.38)
2 Supplemental to human milk
Lucas 1989b 12/132 16/132 61.7 % 0.75 [ 0.37, 1.52 ]
Subtotal (95% CI) 132 132 61.7 % 0.75 [ 0.37, 1.52 ]
Total events: 12 (Nutrient-enriched formula), 16 (Standard formula)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
Total (95% CI) 248 241 100.0 % 0.72 [ 0.41, 1.25 ]
Total events: 21 (Nutrient-enriched formula), 27 (Standard formula)
Heterogeneity: Chi2 = 2.44, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 1.24. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 24 Duration of birth
hospitalisation.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 24 Duration of birth hospitalisation
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kulkarni 1984 13 52 (10.8) 18 51 (17) 100.0 % 1.00 [ -8.81, 10.81 ]
Total (95% CI) 13 18 100.0 % 1.00 [ -8.81, 10.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 25 All-cause
mortality.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 25 All-cause mortality
Study or subgroup
Nutrient-
enriched
formula Standard formula Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 11/81 8/79 40.1 % 1.34 [ 0.57, 3.16 ]
Subtotal (95% CI) 81 79 40.1 % 1.34 [ 0.57, 3.16 ]
Total events: 11 (Nutrient-enriched formula), 8 (Standard formula)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Supplemental to human milk
Lucas 1989b 14/132 14/132 59.9 % 1.00 [ 0.50, 2.01 ]
Subtotal (95% CI) 132 132 59.9 % 1.00 [ 0.50, 2.01 ]
Total events: 14 (Nutrient-enriched formula), 14 (Standard formula)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 213 211 100.0 % 1.12 [ 0.65, 1.93 ]
Total events: 25 (Nutrient-enriched formula), 22 (Standard formula)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 1.26. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 26 Body mass index
(kg/m²) at 18 months post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 26 Body mass index (kg/m2) at 18 months post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 61 16 (1.9) 58 16.1 (1.4) 31.1 % -0.10 [ -0.70, 0.50 ]
Subtotal (95% CI) 61 58 31.1 % -0.10 [ -0.70, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 Supplemental to human milk
Lucas 1989b 105 16 (1.4) 110 16.1 (1.6) 68.9 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 105 110 68.9 % -0.10 [ -0.50, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 166 168 100.0 % -0.10 [ -0.43, 0.23 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 1.27. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 27 Body mass index
(kg/m²) at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 27 Body mass index (kg/m2) at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 15.4 (1.6) 68 15.4 (1.8) 44.2 % 0.0 [ -0.57, 0.57 ]
Subtotal (95% CI) 67 68 44.2 % 0.0 [ -0.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Supplemental to human milk
Lucas 1989b 111 15.6 (2) 113 15.5 (1.9) 55.8 % 0.10 [ -0.41, 0.61 ]
Subtotal (95% CI) 111 113 55.8 % 0.10 [ -0.41, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 178 181 100.0 % 0.06 [ -0.33, 0.44 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 1.28. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 28 Waist-to-hip
ratio at 7.5 to 8 years post term.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 28 Waist-to-hip ratio at 7.5 to 8 years post term
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sole diet
Lucas 1989a 67 0.86 (0.41) 68 0.89 (0.58) 71.3 % -0.03 [ -0.20, 0.14 ]
Subtotal (95% CI) 67 68 71.3 % -0.03 [ -0.20, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 Supplemental to human milk
Lucas 1989b 111 0.88 (1.37) 113 0.87 (0.43) 28.7 % 0.01 [ -0.26, 0.28 ]
Subtotal (95% CI) 111 113 28.7 % 0.01 [ -0.26, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 178 181 100.0 % -0.02 [ -0.16, 0.12 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours Standard formula Favours Nutrient-enriched formula
63Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.29. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 29 Serum alkaline
phosphatase level after 4 weeks (IU/mL).
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 29 Serum alkaline phosphatase level after 4 weeks (IU/mL)
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kashyap 1986 9 287 (107) 9 277 (63) 31.8 % 10.00 [ -71.12, 91.12 ]
Kulkarni 1984 13 305 (72) 18 370 (85) 68.2 % -65.00 [ -120.44, -9.56 ]
Total (95% CI) 22 27 100.0 % -41.12 [ -86.89, 4.65 ]
Heterogeneity: Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Nutrient-enriched formula vs standard formula, Outcome 30 Bone mineral
content (g) assessed by DEXA at 8 to 12 years.
Review: Nutrient-enriched formula versus standard formula for preterm infants
Comparison: 1 Nutrient-enriched formula vs standard formula
Outcome: 30 Bone mineral content (g) assessed by DEXA at 8 to 12 years
Study or subgroup
Nutrient-
enriched
formula Standard formula
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Lumbar spine
Lucas 1989a 25 24 (3.5) 36 26.7 (7.9) 100.0 % -2.70 [ -5.62, 0.22 ]
Subtotal (95% CI) 25 36 100.0 % -2.70 [ -5.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
2 Femoral neck
Lucas 1989a 25 3.3 (0.55) 36 3.2 (0.61) 100.0 % 0.10 [ -0.19, 0.39 ]
Subtotal (95% CI) 25 36 100.0 % 0.10 [ -0.19, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 Radius
Lucas 1989a 24 0.47 (0.09) 33 0.5 (0.08) 100.0 % -0.03 [ -0.08, 0.02 ]
Subtotal (95% CI) 24 33 100.0 % -0.03 [ -0.08, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
4 Whole body
Lucas 1989a 24 1061 (1732) 36 1138 (310) 100.0 % -77.00 [ -777.29, 623.29 ]
Subtotal (95% CI) 24 36 100.0 % -77.00 [ -777.29, 623.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 3.99, df = 3 (P = 0.26), I2 =25%
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A P P E N D I C E S
Appendix 1. Electronic search strategy
MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily
Ovid SP http://ovidsp.ovid.com/
1946 to November 09, 2018
Searched on: 12th November 2018
Records retrieved: 1621
The Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (sensitivity-maximizing version) was
used to limit retrieval to clinical trials (lines 23-32) (Lefebvre 2011).
1 exp Infant, Premature/ (51379)
2 exp Infant, Low Birth Weight/ (31813)
3 Premature Birth/ (11445)
4 (preterm or preterms or pre term or pre terms).ti,ab. (66255)
5 (preemie$ or premie or premies).ti,ab. (152)
6 prematur$.ti,ab. (132614)
7 (low adj3 (birthweight$ or birth weight$)).ti,ab. (31857)
8 (lbw or vlbw or elbw).ti,ab. (7551)
9 or/1-8 (220728)
10 Infant Formula/ (3966)
11 formula$.ti,ab. (279507)
12 artificial milk.ti,ab. (205)
13 or/10-12 (280600)
14 Nutriprem.ti,ab. (3)
15 Enfamil premature.ti,ab. (5)
16 Similac special care.ti,ab. (25)
17 Aptamil preterm.ti,ab. (0)
18 Good Start premature.ti,ab. (0)
19 Preemie SMA.ti,ab. (4)
20 or/14-19 (34)
21 13 or 20 (280603)
22 9 and 21 (4416)
23 randomized controlled trial.pt. (471154)
24 controlled clinical trial.pt. (92744)
25 randomized.ab. (426145)
26 placebo.ab. (193103)
27 drug therapy.fs. (2061284)
28 randomly.ab. (300071)
29 trial.ab. (444246)
30 groups.ab. (1850065)
31 or/23-30 (4315602)
32 exp animals/ not humans/ (4513797)
33 31 not 32 (3730894)
34 22 and 33 (1621)
Key
/ = indexing term (MeSH heading)
exp = exploded MeSH heading
$ = truncation
.ti,ab. = terms in either title or abstract fields
adj3 = terms within three words of each other (any order)
.pt.= terms in the publication type field
.fs.= floating subheading
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Cochrane Central Register of Controlled Trials (CENTRAL)
Wiley http://onlinelibrary.wiley.com/
Issue 11 of 12, November 2018
Searched on: 13th November 2018
Records retrieved: 1171
#1 MeSH descriptor: [Infant, Premature] explode all trees 3394
#2 MeSH descriptor: [Infant, Low Birth Weight] explode all trees 2040
#3 MeSH descriptor: [Premature Birth] this term only 1028
#4 (preterm or preterms or pre next term or pre next terms):ti,ab,kw 9992
#5 (preemie* or premie or premies):ti,ab,kw 34
#6 prematur*:ti,ab,kw 17871
#7 (low near/3 (birthweight* or birth next weight*)):ti,ab,kw 4419
#8 (lbw or vlbw or elbw):ti,ab,kw 1359
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 23148
#10 MeSH descriptor: [Infant Formula] this term only 532
#11 formula*:ti,ab,kw 30550
#12 artificial milk:ti,ab,kw 585
#13 {OR #10-#12} 30669
#14 Nutriprem:ti,ab,kw 0
#15 Enfamil next premature:ti,ab,kw 1
#16 Similac next special next care:ti,ab,kw 16
#17 Aptamil next preterm:ti,ab,kw 0
#18 Good next Start next premature:ti,ab,kw 0
#19 Preemie next SMA:ti,ab,kw 2
#20 {OR #14-#19} 19
#21 #13 OR #20 30669
#22 #9 AND #21 1287
#23 #9 AND #21 in Trials 1171
Line #23 shows the number of hits in CENTRAL only.
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
:ti,ab,kw = terms in either title, abstract or keyword fields
near/3 = terms within three words of each other (any order)
next = terms are next to each other
Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus)
via EBSCO http://www.ebsco.com/
Inception to 12th November 2018
Searched on: 12th November 2018
Records retrieved: 1331
S1 (MH “Infant, Premature”) 19,011
S2 (MH “Infant, Low Birth Weight+”) 11,670
S3 TI ( preterm or preterms or pre-term or pre-terms ) OR AB ( preterm or preterms or pre-term or pre-terms) 25,267
S4 TI ( preemie* or premie or premies ) OR AB ( preemie* or premie or premies ) 257
S5 TI prematur* OR AB prematur* 24,035
S6 TI ( low N3 (birthweight* or birth-weight*) ) OR AB ( low N3 (birthweight* or birth-weight*) ) 9,594
S7 TI ( lbw or vlbw or elbw ) OR AB ( lbw or vlbw or elbw ) 2,590
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 58,200
S9 (MH “Infant Formula”) 3,551
S10 TI formula* OR AB formula* 37,184
S11 TI artificial milk OR AB artificial milk 91
S12 S9 OR S10 OR S11 38,940
S13 TI Nutriprem OR AB Nutriprem 0
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S14 TI Enfamil premature OR AB Enfamil premature 1
S15 TI Similac special care OR AB Similac special care 2
S16 TI Aptamil preterm OR AB Aptamil preterm 0
S17 TI Good Start premature OR AB Good Start premature 1
S18 TI Preemie SMA OR AB Preemie SMA 0
S19 S13 OR S14 OR S15 OR S16 OR S17 OR S18 4
S20 S12 OR S19 38,942
S21 S8 AND S20 1,369
S22 TI rat or rats or mouse or mice or hamster or hamsters or dog or dogs or cat or cats or sheep or lamb or lambs or pig or pigs or
baboon* 65,296
S23 S21 NOT S22 1,331
Key
MH = indexing term (CINAHL heading)
+ = exploded CINAHL heading
* = truncation
TI = words in the title
AB = words in the abstract
N3 = terms within three words of each other (any order)
Embase
Ovid SP http://ovidsp.ovid.com/
1974 to 2018 November 09
Searched on: 12th November 2018
Records retrieved: 1937
The Cochrane EMBASE search strategy for identifying trials for populating CENTRAL ( https://www.cochranelibrary.com/central/
central-creation) was used as a basis to limit retrieval to clinical trials (lines 22-42).
1 prematurity/ (90414)
2 exp low birth weight/ (55443)
3 (preterm or preterms or pre term or pre terms).ti,ab. (91844)
4 (preemie$ or premie or premies).ti,ab. (227)
5 prematur$.ti,ab. (170179)
6 (low adj3 (birthweight$ or birth weight$)).ti,ab. (39584)
7 (lbw or vlbw or elbw).ti,ab. (10182)
8 or/1-7 (292071)
9 artificial milk/ (12653)
10 formula$.ti,ab. (349334)
11 artificial milk.ti,ab. (229)
12 or/9-11 (353323)
13 Nutriprem.ti,ab. (5)
14 Enfamil premature.ti,ab. (5)
15 Similac special care.ti,ab. (29)
16 Aptamil preterm.ti,ab. (0)
17 Good Start premature.ti,ab. (0)
18 Preemie SMA.ti,ab. (4)
19 or/13-18 (40)
20 12 or 19 (353325)
21 8 and 20 (6391)
22 randomized controlled trial/ (522152)
23 controlled clinical trial/ (458440)
24 Random$.ti,ab. (1348777)
25 randomization/ (80039)
26 intermethod comparison/ (241195)
27 placebo.ti,ab. (278696)
28 (compare or compared or comparison).ti. (463938)
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29 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab. (1821129)
30 (open adj label).ti,ab. (67066)
31 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. (211971)
32 double blind procedure/ (155043)
33 parallel group$1.ti,ab. (22476)
34 (crossover or cross over).ti,ab. (94851)
35 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or partici-
pant$1)).ti,ab. (291657)
36 (assigned or allocated).ti,ab. (342490)
37 (controlled adj7 (study or design or trial)).ti,ab. (304046)
38 (volunteer or volunteers).ti,ab. (227887)
39 human experiment/ (422751)
40 trial.ti. (255652)
41 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 (4418563)
42 (animal/ or nonhuman/) not exp human/ (5251547)
43 41 not 42 (3905510)
44 21 and 43 (1937)
Key:
/ = indexing term (EMTREE heading)
exp = exploded EMTREE heading
$ = truncation
$1 = limited truncation - 1 character on none after word stem.
.ti,ab. = terms in either title or abstract fields
adj3 = terms within three words of each other (any order)
Maternity and Infant Care
Ovid SP http://ovidsp.ovid.com/
1971 to September 2018
Searched on: 12 November 2018
Records retrieved: 1060
1 (preterm or preterms or pre term or pre terms).mp. (24959)
2 (preemie$ or premie or premies).mp. (52)
3 prematur$.mp. (22204)
4 (low adj3 (birthweight$ or birth weight$)).mp. (11426)
5 (lbw or vlbw or elbw).mp. (2918)
6 or/1-5 (40035)
7 formula$.mp. (6140)
8 artificial milk.mp. (50)
9 7 or 8 (6180)
10 Nutriprem.mp. (3)
11 Enfamil premature.mp. (1)
12 Similac special care.mp. (6)
13 Aptamil preterm.mp. (0)
14 Good Start premature.mp. (0)
15 Preemie SMA.mp. (0)
16 10 or 11 or 12 or 13 or 14 or 15 (9)
17 9 or 16 (6181)
18 6 and 17 (1060)
Key
$ = truncation
.mp. = multi-purpose field search - includes terms in either title, abstract, keyword heading, name of substance, original title or subject
heading fields
adj3 = terms within three words of each other (any order)
PubMed
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http://www.ncbi.nlm.nih.gov/pubmed/
Searched on: 12 November 2018
Records retrieved: 63
The Cochrane Highly Sensitive Search Strategy for identifying randomised trials in PubMed (sensitivity-maximizing version) was used
to limit retrieval to clinical trials (Lefebvre 2011). The search was limited to those records found in PubMed but not Medline (Duffy
2016).
Search ((((((((((“Infant Formula”[Mesh:NoExp]) OR formula*[Title/Abstract]) OR artificial milk[Title/Abstract])) OR ((((((Nu-
triprem[Title/Abstract]) OR Enfamil premature[Title/Abstract]) OR Similac special care[Title/Abstract]) OR Aptamil preterm[Title/
Abstract]) OR Good Start premature[Title/Abstract]) OR Preemie SMA[Title/Abstract]))) AND ((((((((“Infant, Premature”[Mesh])
OR “Infant, Low Birth Weight”[Mesh]) OR “Premature Birth”[Mesh:NoExp]) OR ((preterm[Title/Abstract] OR preterms[Title/Ab-
stract] OR “pre term”[Title/Abstract] OR “pre terms”[Title/Abstract]))) OR ((preemie*[Title/Abstract] OR premie[Title/Abstract] OR
premies[Title/Abstract]))) OR prematur*[Title/Abstract]) OR ((low[Title/Abstract]) AND (birthweight*[Title/Abstract] OR birth-
weight*[Title/Abstract]))) OR ((lbw[Title/Abstract] OR vlbw[Title/Abstract] OR elbw[Title/Abstract]))))) AND (((((((((((random-
ized controlled trial[Publication Type])) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR
(placebo[Title/Abstract])) OR (drug therapy[MeSH Subheading])) OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR
(groups[Title/Abstract]))) NOT (animals[mh] NOT humans[mh])))) AND ((pubstatusaheadofprint OR publisher[sb] OR pubmed-
notmedline[sb]))
Appendix 2. ‘Risk of bias’ tool
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we will categorise the method used to generate the allocation sequence as follows.
• Low risk (any truly random process, e.g. random number table; computer random number generator).
• High risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number).
• Unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we will categorise the method used to conceal the allocation sequence as follows.
• Low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes).
• High risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth).
• Unclear risk.
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we will categorise the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding will be assessed separately for different outcomes or class of outcomes. We will categorise
the methods as follows.
• Low risk, high risk, or unclear risk for participants.
• Low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we will categorise the methods used to blind outcome assessment. Blinding will be assessed separately for
different outcomes or class of outcomes. We will categorise the methods as follows.
• Low risk for outcome assessors.
• High risk for outcome assessors.
• Unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were
incomplete outcome data adequately addressed?
For each included study and for each outcome, we will describe the completeness of data including attrition and exclusions from the
analysis. We will note whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared
with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced
across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we will re-include
missing data in the analyses. We will categorise the methods as follows.
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• Low risk (< 20% missing data).
• High risk (≥ 20% missing data).
• Unclear risk.
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?
For each included study, we will describe how we investigated the possibility of selective outcome reporting bias and what we found.
For studies in which study protocols were published in advance, we will compare prespecified outcomes versus outcomes eventually
reported in the published results. If the study protocol was not published in advance, we will contact study authors to gain access to
the study protocol. We will assess the methods as follows.
• Low risk (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have
been reported).
• High risk (where not all the study’s prespecified outcomes have been reported; one or more reported primary outcomes were not
prespecified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported).
• Unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at high risk of bias?
For each included study, we will describe any important concerns we had about other possible sources of bias (e.g. whether there was a
potential source of bias related to the specific study design, whether the trial was stopped early due to some data-dependent process).
We will assess whether each study was free of other problems that could put it at risk of bias as follows.
• Low risk.
• High risk.
• Unclear risk.
If needed, we will explore the impact of the level of bias through undertaking sensitivity analyses.
Appendix 3. GRADE
The GRADE approach generates an assessment of the certainty of a body of evidence to one of four grades.
• High: we are very confident that the true effect lies close to that of the estimate of the effect.
• Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
• Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 7, 2019
Date Event Description
20 March 2019 Amended Protocol rewritten by new review author team to update and supersede Simmer 2003
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Mortality until 18 months included.
73Nutrient-enriched formula versus standard formula for preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
